STOCK TITAN

Pliant Therapeutics, Inc. - PLRX STOCK NEWS

Welcome to our dedicated page for Pliant Therapeutics news (Ticker: PLRX), a resource for investors and traders seeking the latest updates and insights on Pliant Therapeutics stock.

Pliant Therapeutics, Inc. (NASDAQ: PLRX) is a clinical-stage biopharmaceutical company pioneering novel therapies for fibrotic diseases through integrin biology and TGF-β pathway modulation. This page serves as the definitive source for official updates on their research pipeline, clinical trial progress, and regulatory developments.

Investors and researchers will find timely announcements about bexotegrast (PLN-74809), the company’s dual αvβ6/αvβ1 integrin inhibitor currently in Phase 2b trials for idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). The resource also covers updates across PLRX’s broader pipeline targeting liver fibrosis, oncology, and neuromuscular conditions.

Key content includes press releases on clinical milestones, peer-reviewed publication highlights, and strategic collaborations. All materials are sourced directly from company disclosures to ensure accuracy and compliance with financial reporting standards.

Bookmark this page for streamlined access to PLRX’s latest advancements in small molecule therapeutics. Check regularly for updates on trial enrollment completions, data readouts, and FDA communications related to their antifibrotic programs.

Rhea-AI Summary

Pliant Therapeutics (Nasdaq: PLRX) has announced its participation in the 2025 American Thoracic Society (ATS) International Conference in San Francisco from May 16-21, 2025. The company will present three scientific works, including:

1. A featured oral presentation by Dr. Johanna Schaub on Bexotegrast's antifibrotic activity in ILD subtypes (May 19, 2:15-4:15 PM PT)

2. A poster presentation by Dr. Richard Ahn on plasma proteome analysis of ILD subtypes (May 21, 8:15-10:15 AM PT)

3. A poster by Dr. Mahru An on single-cell profiling of Bexotegrast's antifibrotic effects (May 21, 8:15-10:15 AM PT)

All presentations will be available for registered conference attendees and later on Pliant's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2%
Tags
conferences
-
Rhea-AI Summary

Pliant Therapeutics (PLRX) has announced promising interim Phase 1 data for PLN-101095, their integrin αvβ8 and αvβ1 inhibitor, in combination with pembrolizumab for treating immune checkpoint inhibitor-refractory advanced solid tumors.

Key findings from the first three cohorts include:

  • 50% objective response rate at the highest tested dose (1000mg BID)
  • Three confirmed partial responses observed in cohort three, with patients showing tumor size reductions of:
    • 74% in Non-Small Cell Lung Cancer at Week 18
    • 48% in Cholangiocarcinoma at Week 42
    • 42% in Melanoma at Week 27
  • PLN-101095 was generally well tolerated across all doses

The trial enrolled nine patients with six different tumor types across three cohorts, testing doses of 250mg, 500mg, and 1000mg BID. The study is currently enrolling its fourth cohort, evaluating PLN-101095 at 1000mg three times daily.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.39%
Tags
-
Rhea-AI Summary

Pliant Therapeutics (PLRX) has announced the adoption of a duration stockholder rights agreement ('poison pill') by its Board of Directors, effective until March 11, 2026. The measure comes in response to recent stock accumulations and aims to prevent unauthorized control through market purchases.

Under the agreement, stockholders of record by March 25, 2025, will receive one preferred share purchase right per common stock share. These rights activate if an entity acquires 10% ownership (20% for Schedule 13G investors) without Board approval. In such cases, existing stockholders can purchase additional PLRX shares at a 50% discount. Similar provisions apply if Pliant is acquired in a merger after such unauthorized accumulation.

The Board retains the right to redeem these rights at $0.001 per right or exchange them at one common share per right. Existing stockholders above threshold levels will be grandfathered, unless they increase their holdings after the announcement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.8%
Tags
none
Rhea-AI Summary

Pliant Therapeutics (PLRX) has announced the discontinuation of its BEACON-IPF Phase 2b trial following recommendations from both the data safety monitoring board and an outside expert panel. The trial was halted due to an imbalance in IPF-related adverse events between treatment and placebo groups, though early efficacy signals were observed in forced vital capacity endpoints.

The company continues to advance its other programs, including a Phase 1 trial of PLN-101095 in solid tumors, currently in its fourth of five planned dose cohorts, with interim data expected in Q1 2025. Additionally, PLN-101325 for muscular dystrophies is Phase 1 ready with clinical trial approval in Australia.

Financial results for Q4 2024 show R&D expenses of $38.8M (up from $33.2M YoY) and G&A expenses of $14.5M (up from $13.9M YoY). Net loss increased to $49.7M from $41.1M in the prior-year quarter. The company maintains a strong financial position with $357.2M in cash and investments, expected to fund operations beyond 12 months.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.17%
Tags
-
Rhea-AI Summary

Pliant Therapeutics (PLRX) has discontinued its BEACON-IPF Phase 2b trial of bexotegrast in idiopathic pulmonary fibrosis (IPF) patients following safety concerns, despite showing early efficacy signs in forced vital capacity (FVC). The discontinuation came after reviews by the trial's Data Safety Monitoring Board and an external expert panel.

The trial, with approximately 17 weeks mean exposure duration, showed comparable IPF-related adverse events (around 10%) in both dose groups. However, an imbalance was noted due to unusually low adverse event rates (<3%) in the placebo group. This contrasts with the Phase 2a INTEGRIS-IPF trial, where adverse events were similar between bexotegrast-treated (7%) and placebo groups (10%).

The company plans to analyze the complete data and consider additional Phase 2b studies with lower doses for pulmonary fibrosis and other non-respiratory indications. Meanwhile, Pliant continues developing other assets, including PLN-101095 in oncology, currently in Phase 1 trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-59.88%
Tags
-
Rhea-AI Summary

Pliant Therapeutics (PLRX) has initiated the assembly of an external expert panel to review unblinded data from the ongoing BEACON-IPF Phase 2b trial of bexotegrast in idiopathic pulmonary fibrosis (IPF) patients. This decision follows a recommendation from the trial's independent Data Safety Monitoring Board (DSMB) to pause enrollment and dosing.

The company has been unable to determine the rationale for the DSMB's recommendation through review of blinded data. The newly assembled panel, comprising experts in pulmonary diseases and biostatistics, will provide an independent recommendation and subsequently join an expanded DSMB to reach a consensus recommendation regarding BEACON-IPF.

The process is expected to conclude in 2-4 weeks. Pliant has voluntarily paused enrollment and dosing while maintaining trial blinding to preserve data integrity and the trial's potential registrational status.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.96%
Tags
Rhea-AI Summary

Pliant Therapeutics (PLRX) has announced a voluntary pause in enrollment and dosing in its BEACON-IPF Phase 2b trial of bexotegrast for idiopathic pulmonary fibrosis (IPF) patients. This decision follows recommendations from the trial's independent Data Safety Monitoring Board (DSMB) after a prespecified data review.

Currently enrolled patients will remain in the trial while the company reviews data to understand the DSMB's recommendation. The study will maintain its blinding to preserve trial integrity. The company has informed trial investigators and is notifying global regulatory authorities about this development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-60.59%
Tags
-
Rhea-AI Summary

Pliant Therapeutics (PLRX) has granted stock options to its newly appointed Chief Technical Officer, Delphine Imbert, Ph.D., as part of her employment package. The grant includes options to purchase 275,000 shares of common stock at an exercise price of $11.07 per share, matching the company's closing price on January 21, 2025.

The options will vest over a 4-year period, with 25% vesting after the first year and the remaining shares vesting monthly at a rate of 1/48th over the subsequent 36 months, contingent on continued employment. The options have a 10-year term and are subject to the Company's 2022 Inducement Plan terms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.01%
Tags
none
-
Rhea-AI Summary

Pliant Therapeutics (PLRX) has appointed Delphine Imbert, Ph.D. as Chief Technical Officer. Dr. Imbert brings 25 years of strategic clinical to commercial-stage manufacturing and drug development experience across multiple drug modalities. In her new role, she will lead chemistry, manufacturing and control (CMC)-related activities supporting Pliant's commercial-stage readiness plan.

Dr. Imbert most recently served as Senior Vice President of CMC and Technical Operations at Chinook Therapeutics (acquired by Novartis), where she managed a fully outsourced CMC, manufacturing and supply chain organization. Previously, she held senior roles at Dermira (acquired by Eli Lily) and Anacor Pharmaceuticals (acquired by Pfizer), demonstrating expertise in pharmaceutical development, manufacturing processes, supply chain, logistics, and regulatory filings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.36%
Tags
management
Rhea-AI Summary

Pliant Therapeutics (PLRX) has announced its participation in the upcoming 43rd Annual J.P. Morgan Healthcare Conference. Bernard Coulie, M.D., Ph.D., the company's President and Chief Executive Officer, will deliver a presentation on Tuesday, January 14, 2025, at 1:30 p.m. Pacific Time at the Westin St. Francis Hotel in San Francisco.

Interested investors and stakeholders can access the presentation through a live webcast available on the Investors & Media section of Pliant's website at www.PliantRx.com. The presentation recording will remain accessible on the website for 30 days after the event concludes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
conferences
Pliant Therapeutics, Inc.

Nasdaq:PLRX

PLRX Rankings

PLRX Stock Data

89.40M
58.09M
3.27%
117.06%
5.37%
Biotechnology
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO